Rigel Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stock-based Compensation (Tables)

Stock-based Compensation (Tables)

6 Months Ended

Jun. 30, 2016

Schedule of stock-based compensation expense related to all of the entity's share-based awards

Total stock-based compensation expense related to all of our share-based payments that we recognized for the three and six months ended June 30, 2016 and 2015 were as follows (in thousands):


	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2016		2015		2016		2015
Research and development	$	1,410	$	1,056	$	2,103	$	2,216
General and administrative		604		853		1,349		1,747
Total stock-based compensation expense	$	2,014	$	1,909	$	3,452	$	3,963

Summary of weighted-average assumptions relating to options granted pursuant to equity incentive plans


	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2016		2015		2016		2015
Risk-free interest rate	1.5	%	1.9	%	1.7	%	1.8	%
Expected term (in years)	7.0		7.0		6.4		6.5
Dividend yield	0.0	%	0.0	%	0.0	%	0.0	%
Expected volatility	76.9	%	66.9	%	63.3	%	65.1	%

Summary of weighted-average assumptions used to calculate fair value of purchase rights granted under Employee Stock Purchase Plan


	Six Months Ended
	June 30,
	2016		2015
Risk-free interest rate	0.7	%	0.6	%
Expected term (in years)	1.8		1.5
Dividend yield	0.0	%	0.0	%
Expected volatility	61.5	%	61.2	%